Theravance Biopharma, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
Granted 75.0K
Granted 37.5K
Granted 37.5K
Granted 18.8K · Sold 44.4K
Granted 18.8K
Granted 6.0K
Granted 6.0K
Granted 6.0K
Granted 6.0K
Granted 6.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Winningham Rick ECHIEF EXECUTIVE OFFICER, Director · 3 transactions | +2.1% | 1.73M | 75.0K | — | — |
| Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · 3 transactions | +6.2% | 355.2K | 37.5K | — | — |
| Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · 3 transactions | +6.6% | 336.8K | 37.5K | — | — |
| Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · 9 transactions | -14% | 226.8K | 18.8K | — | 44.4K |
| Miller AineSVP, DEV & HEAD OF IRE OFFICE · 3 transactions | +3.1% | 189.8K | 18.8K | — | — |
| Mitchell Dean JDirector · 1 transaction | +6.6% | 97.2K | 6.0K | — | — |
| Smaldone Alsup LaurieDirector · 1 transaction | +8% | 81.0K | 6.0K | — | — |
| O'Connor DonalDirector · 1 transaction | +8.1% | 80.2K | 6.0K | — | — |
| Pakianathan DeepikaDirector · 1 transaction | +10.3% | 64.1K | 6.0K | — | — |
| Gray SusannahDirector · 1 transaction | +14.3% | 48.1K | 6.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -44.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.